Printable Schedule-at-a-Glance (Updated 8/27/2015)
WEDNESDAY, NOV. 4, 2015
Welcome Reception (provided)
Group Dinner (provided)
THURSDAY, NOV. 5, 2015 — Up to 6.5 CME/ACPE/CE credits available — ACPE UAN 0860-0000-15-020-L01-P
Registration and Continental Breakfast
Welcome and Opening Remarks
Keynote Address — The Evolution and Transmission of Antibiotic Resistance: How Can We Manage this Public Health Threat? Jean Patel, PhD, D(ABMM), Centers for Disease Control and Prevention
Antibiotics have saved millions of lives from once-deadly infectious diseases; however, misuse of antibiotics and other antimicrobials has led to bacteria evolving resistance. Antibiotic-resistant bacteria have become a threat to global public health — they are a major cause of morbidity and mortality in hospitalized patients and individuals in community settings, and consume more health care resources than patients infected with the same bacteria that are not resistant.
During this keynote address, Dr. Patel will discuss the clinical and economic impact of drug-resistant bacteria on the health care system, as well as prevention and intervention strategies that health care professionals can put into place to try to reduce the pervasiveness of these infections.
New Medications in the Management of Diabetes in Adults, Anne Peters, MD, Keck School of Medicine of USC
Treatment of type 2 diabetes mellitus (T2DM) continues to present challenges, and a significant proportion of patients fail to achieve and maintain glycemic targets. Despite the availability of many oral antidiabetic agents, therapeutic efficacy is offset by side effects, such as weight gain and hypoglycemia. There have, however, been several recent advances that offer potentially significant quality-of-life improvements to the diabetic patient. These agents include dipeptidyl peptidase-4 (DPP-4) inhibitors that have a confined effect on lowering blood glucose and neutral effect on caloric intake; and sodium-glucose cotransporter 2 (SGLT2) inhibitors, which reduce hyperglycemia by increasing urinary glucose excretion independently of insulin secretion or action. During this session, the mechanism of action of new medications for T2DM will be explained, along with other important factors in the management of this disease.
Physician Burnout: The Epidemic of Severely Stressed Physicians, Tait D. Shanafelt, MD, Mayo Clinic
A study published in JAMA Internal Medicine in 2012 indicated that burnout is more common among physicians than among other U.S. workers, with nearly half of the physicians surveyed reporting at least one symptom of burnout. Physicians in specialties at the front line of care access seem to be at greatest risk for this epidemic with respect to stress and burnout. Depression and demoralization drive some physicians into early retirement and undermine the quality of patient care by eroding doctors’ compassion and attention to detail. This session will discuss the causes that influence physician stress, the incidence of this epidemic and interventions that may be applied to help alleviate this issue.
Lunch and Exhibits (lunch provided)
Coronary Heart Disease Risk Assessment and Prevention: Current State of the Art, Gregg C. Fonarow, MD, FACC, FAHA, University of California, Los Angeles
The American Heart Association (AHA) and the American College of Cardiology (ACC) recently developed comprehensive treatment recommendations to help health care providers (HCPs) predict and reduce risk for coronary heart disease. These practice-changing recommendations that patients be evaluated for heart disease risk and treated accordingly have caused both confusion and concern among HCPs. The use of a risk calculator — which incorporates such factors as blood pressure, lipid levels, and whether diabetes is present — to assess a person’s risk of developing coronary heart disease and the need for taking cholesterol-lowering drugs has come under question by some for overestimating risk. Based on the new ACC/AHA recommendations, as many as 31 million people may be candidates for statins. Understanding that no algorithm that tries to predict risk is 100 percent accurate, this presentation will discuss the rationale behind the new guidelines and the roadblocks that are still being faced with their successful implementation.
Rheumatoid Arthritis: Are We Making Progress in Managing this Autoimmune Disease? Michael H. Weisman, MD, Cedars-Sinai Medical Center
The National Institutes of Health (NIH) estimates that up to 23.5 million Americans suffer from autoimmune disease (AD) and that the prevalence is rising. The annual direct health care costs for AD are estimated to be in the range of $100 billion. Autoimmune disease is a pathologic condition caused by an autoimmune response — an adaptive immune response directed against an antigen within the body of the host (termed a self-antigen). The exact etiology of autoimmune disorders is unknown. Researchers have identified 80–100 different ADs that are chronic and can be life threatening.
With a focus on rheumatoid arthritis (RA), this presentation will review evidence-based treatment guidelines, examine scientific and clinical advances, and identify factors that may improve clinical outcomes and decrease costs in the management of RA.
Medication Nonadherence: Are There Effective Interventions that Can Address this Costly, Preventable and Potentially Deadly Behavior? Leah L. Zullig, PhD, MPH, Duke University Medical Center
A survey commissioned by the National Community Pharmacists Association in 2013 reported that millions of adults aged 40 years and older with chronic conditions are departing from physicians’ instructions in taking their medications; failing to fill or refill prescriptions; under- or overdosing; or taking medication prescribed for a different condition or to a different person. Medication nonadherence is a costly (costs are estimated at $290 billion dollars annually) and potentially deadly, yet preventable action. This presentation will outline the barriers, costs and negative health outcomes associated with poor adherence, as well as review the vital role that physicians, pharmacists, and other health care providers have to play in enhancing adherence.
The Role of Genetic Testing for Cancer Susceptibility, Rebecca Sutphen, MD, FACMG, Informed Medical Decisions, Inc.
Breast and ovarian cancers are leading causes of death among women. A possible genetic contribution that may increase a woman’s risk of these cancers is her family history and the BRCA1 or BRCA2 mutation. This presentation will address the implications a harmful BRCA1 or BRCA2 mutation has on developing breast and/or ovarian cancer and their effect on prognosis and treatment, as well as highlight the benefits and limitations of genetic screening for these mutations.
Reception and Exhibits (reception provided)
Note: OptumHealth Education reserves the right to make any necessary changes to this program. Efforts will be made to keep presentations as scheduled. However, unforeseen circumstances may result in the substitution of faculty or content.